Q1 EPS Estimates for Vera Therapeutics Cut by HC Wainwright

Vera Therapeutics, Inc. (NASDAQ:VERA) – Analysts at HC Wainwright cut their Q1 2026 EPS estimates for shares of Vera Therapeutics in a research report issued on Monday, March 2nd. HC Wainwright analyst A. He now forecasts that the company will post earnings per share of ($1.35) for the quarter, down from their previous forecast of ($0.98). HC Wainwright has a “Buy” rating and a $110.00 price target on the stock. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share. HC Wainwright also issued estimates for Vera Therapeutics’ Q2 2026 earnings at ($1.31) EPS, Q3 2026 earnings at ($1.26) EPS, Q4 2026 earnings at ($0.93) EPS, FY2026 earnings at ($4.84) EPS, FY2027 earnings at ($1.53) EPS, FY2028 earnings at $2.04 EPS, FY2029 earnings at $8.43 EPS and FY2030 earnings at $9.88 EPS.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Wednesday, February 25th. The company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.05). During the same period last year, the company posted ($0.72) EPS.

Several other equities research analysts have also recently weighed in on VERA. JPMorgan Chase & Co. lowered their target price on Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating for the company in a report on Friday, December 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Wednesday, January 21st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vera Therapeutics in a report on Wednesday, November 26th. TD Cowen restated a “buy” rating on shares of Vera Therapeutics in a report on Friday, December 5th. Finally, Bank of America upped their price target on shares of Vera Therapeutics from $48.00 to $66.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Nine analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $80.80.

Vera Therapeutics Stock Down 2.0%

Shares of NASDAQ VERA opened at $38.85 on Thursday. Vera Therapeutics has a 52-week low of $18.53 and a 52-week high of $56.05. The firm has a market capitalization of $2.72 billion, a price-to-earnings ratio of -8.34 and a beta of 1.17. The stock has a 50 day moving average price of $45.12 and a 200 day moving average price of $36.00. The company has a debt-to-equity ratio of 0.12, a quick ratio of 13.64 and a current ratio of 13.64.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC increased its stake in shares of Vera Therapeutics by 50.5% during the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after purchasing an additional 236 shares in the last quarter. Los Angeles Capital Management LLC purchased a new position in Vera Therapeutics in the 4th quarter valued at about $46,000. Quantbot Technologies LP acquired a new stake in Vera Therapeutics in the 2nd quarter worth about $51,000. Aster Capital Management DIFC Ltd acquired a new stake in Vera Therapeutics in the 4th quarter worth about $71,000. Finally, Virtus Investment Advisers LLC increased its stake in Vera Therapeutics by 14.8% during the 2nd quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock worth $98,000 after buying an additional 539 shares in the last quarter. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Vera Therapeutics

In related news, CFO Sean Grant sold 4,949 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $41.98, for a total transaction of $207,759.02. Following the completion of the transaction, the chief financial officer owned 114,181 shares in the company, valued at $4,793,318.38. The trade was a 4.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Patrick G. Enright bought 5,882 shares of the stock in a transaction on Thursday, December 11th. The stock was purchased at an average price of $42.50 per share, with a total value of $249,985.00. Following the completion of the purchase, the director owned 5,882 shares of the company’s stock, valued at $249,985. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have sold 33,490 shares of company stock worth $1,405,910. 16.30% of the stock is owned by corporate insiders.

Vera Therapeutics News Summary

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: Board hire strengthens corporate and financial experience — Vera named Christopher Hite to its board; Hite brings decades of biopharma corporate and financial-strategy leadership, which may help with capital markets strategy, partnerships and commercialization planning. Vera Therapeutics Appoints Christopher Hite to Board of Directors
• Positive Sentiment: Analyst raised long‑run earnings projections — HC Wainwright increased its FY2029 and FY2030 EPS forecasts materially (FY2029 to $8.43, FY2030 to $9.88), signaling the firm still models substantial product upside over the next several years. MarketBeat Vera Therapeutics Coverage
• Neutral Sentiment: Analyst maintains Buy rating and high price target — Despite multiple near‑term cuts, HC Wainwright kept a “Buy” rating and a $110 price objective, offering continued external validation for longer‑term upside even as model timing shifts. Vera Therapeutics (NASDAQ:VERA) Stock Price Expected to Rise, HC Wainwright Analyst Says
• Negative Sentiment: Significant cuts to near‑term earnings and FY2026 — HC Wainwright materially lowered EPS estimates across Q1–Q4 2026 and cut its FY2026 view (now a larger loss of ($4.84)/share vs prior forecast). These downward revisions suggest higher near‑term spend, later revenues, or clinical/timing delays, which weighs on short‑term valuation. MarketBeat Vera Therapeutics Coverage
• Negative Sentiment: Lowered FY2027–FY2028 estimates too — HC Wainwright also cut FY2027 and FY2028 EPS forecasts (FY2027 now projected as a loss), indicating a pushout of profitable commercialization in the firm’s model and creating additional near‑to‑medium term execution risk. MarketBeat Vera Therapeutics Coverage

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.